GLOW Quick Start
GLOW is a single co-formulated blend of three tissue-repair compounds — BPC-157, GHK-Cu, and TB-500 — supplied as one product in both vial and nasal-spray formats. It is dosed as one product; the sections below break out how much of each component a standard dose delivers, based on the vial content.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
GLOW Composition
Each GLOW vial contains 70 mg total in a 5:1:1 ratio. The blend is GHK-Cu-dominant by weight, which is why it is most associated with skin and tissue-quality research.
| Component | Vial content | Share of blend | Primary research focus |
|---|---|---|---|
| GHK-Cu | 50 mg | 71% | Skin / collagen remodeling |
| BPC-157 | 10 mg | 14% | Tendon / gut / vessel repair |
| TB-500 | 10 mg | 14% | Cell migration / soft tissue |
GLOW Dosing Protocols
The injectable, pen-vial and nasal-spray formats are documented as separate protocols, both dosed once daily. Because GLOW is a fixed blend, one dose delivers all three components at the 5:1:1 ratio. The per-component amounts are shown in the next section.
Injection — Subcutaneous
| Band | Units (U-100) | Blend | GHK-Cu | BPC-157 | TB-500 | Frequency |
|---|---|---|---|---|---|---|
| Low | 5 u | 1.17 mg | 0.83 mg | 167 mcg | 167 mcg | Once daily |
| Reference | 10 u | 2.33 mg | 1.67 mg | 333 mcg | 333 mcg | Once daily |
| High | 15 u | 3.5 mg | 2.5 mg | 500 mcg | 500 mcg | Once daily |
Nasal Spray
| Band | Per dose | # of sprays | Frequency |
|---|---|---|---|
| Low | 1.4 mg blend | 2 sprays | Once daily |
| Reference | 2.1 mg blend | 3 sprays | Once daily |
| High | 3.5 mg blend | 5 sprays | Once daily |
Pen Vial — Pre-Reconstituted 3 mL
| Band | Per dose (units) | Delivers | Frequency |
|---|---|---|---|
| Low | 5 units | 1.17 mg blend | Once daily |
| Reference | 10 units | 2.33 mg blend | Once daily |
| High | 15 units | 3.5 mg blend | Once daily |
Cycle planning typically mirrors the tissue-repair components: 4–6 week blocks with 2–4 week off-periods. No human cycling RCT exists for the blend.
Per-Component Dosage Breakdown
This is the dose of each individual compound a standard GLOW dose delivers, derived from the 70 mg vial content and the 5:1:1 ratio, with the typical standalone research range for context.
Injection — 10 units (0.10 mL) once daily
| Component | Per dose | Typical standalone | Assessment |
|---|---|---|---|
| GHK-Cu | 1.67 mg | 1–2 mg daily | In range |
| BPC-157 | 0.33 mg (330 mcg) | ~250 mcg | In range |
| TB-500 | 0.33 mg (330 mcg) | 2–2.5 mg / dose | Light (low maintenance level) |
Nasal Spray — 3 sprays once daily
| Component | Per spray | Per dose (3 sprays) | Standalone |
|---|---|---|---|
| GHK-Cu | 0.5 mg | 1.5 mg | 1–2 mg |
| BPC-157 | 0.1 mg | 0.3 mg (300 mcg) | ~250 mcg |
| TB-500 | 0.1 mg | 0.3 mg (300 mcg) | 2–2.5 mg |
GLOW Reconstitution Guide
Injection
| BAC | Conc. | 10 u dose |
|---|---|---|
| 3 mL | 23.3 mg/mL | 0.10 mL · 2.33 mg |
One reconstitution, one daily draw. Units are U-100.
Pen Vial — 3 mL
| Format | Conc. | 10 u dose |
|---|---|---|
| 3 mL (as supplied) | 23.3 mg/mL | 0.10 mL · 2.33 mg |
Ships pre-reconstituted; no BAC water is added. 33 / 167 / 33 mcg per unit on a U-100 scale.
Reconstitution steps
- Inspect the vial. Confirm label and intact powder (a blue tint from GHK-Cu is expected).
- Wipe the stoppers. Alcohol swab on both vials.
- Draw BAC water. 3 mL into the injectable vial.
- Inject down the wall. Release water slowly down the inside wall, not onto the powder.
- Swirl, do not shake. Roll gently until clear.
- Refrigerate. Store at 2–8 °C; do not freeze.
How to use the pen vial
- Inspect the vial. Confirm the label and strength. A blue tint from the GHK-Cu component is expected — the solution should still be clear, not cloudy.
- Never add water. A pen vial ships at its final 3 mL volume. Adding bacteriostatic water would dilute it and invalidate every unit figure on this page.
- Load the vial into the pen. Unscrew the pen's cartridge holder, seat the vial, and screw the holder back on until firm.
- Attach a fresh needle tip. Screw a new disposable pen needle onto the holder, then pull off the outer and inner caps. Use a new tip for every dose.
- Prime the pen. Dial 2 units, hold the pen needle-up, tap the holder so any air rises to the top, and press the button until a drop appears at the tip. Repeat until it does.
- Spin to the dose. Turn the dial to the unit figure from the table above. If you overshoot, spin back — never press the button to correct an overshoot.
- Inject and hold. Press the button all the way down, then keep the needle in place for about ten seconds before withdrawing so the full dose is delivered.
- Remove and dispose of the needle. Unscrew the tip into a sharps container. Never store the pen with a needle attached — it lets solution leak out and air in.
- Cap and refrigerate. Store the pen with the vial still seated at 2–8 °C. Do not freeze.
How to use the nasal spray
- Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
- Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
- Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
- Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
- Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
- Between uses. Wipe the tip, recap, and refrigerate.
See the bacteriostatic water guide for diluent handling, or the reconstitution calculator to work any other volume.
Why These Three Together
GLOW pairs three compounds with complementary tissue-repair mechanisms. GHK-Cu drives collagen and matrix remodeling, BPC-157 supports angiogenesis and gut/vascular repair, and TB-500 supports cell migration via actin regulation. The combination is a convenience format for tissue-quality research planning rather than a clinically validated fixed-dose drug.
GHK-Cu
Collagen/elastin synthesis and skin remodeling (dominant by weight).
BPC-157
Angiogenesis and gut/vessel repair signaling.
TB-500
Actin-mediated cell migration into injured tissue.
Open question
The blend has no dedicated human trial; rationale is component-level.
Who Should Avoid GLOW
Tested athletes
TB-500 is on the WADA Prohibited List; the blend is therefore prohibited in sport.
Active or prior cancer
Angiogenesis/proliferation pathways across components are a theoretical concern.
Copper-metabolism disorders
GHK-Cu adds copper; avoid in Wilson's disease.
Pregnancy & lactation
No human safety data.
GLOW Side Effects & Safety
Injection-site reactions
Redness or stinging; rotate sites. The GHK-Cu component can sting more than the others.
Combined profile
Side effects reflect all three components; review each component's page.
Copper exposure
GHK-Cu-dominant, so cumulative copper applies; off-periods are common.
Quality-control risk
Verify blend identity and purity against a Certificate of Analysis.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C long-term; fridge short-term | Blue tint from GHK-Cu is normal. |
| Reconstituted (liquid) | 2–8 °C | Use within ~3–4 weeks; do not freeze. |
| Appearance | Clear blue solution | Discard cloudy or particulate solutions. |
Frequently Asked Questions
Is GLOW three separate vials?
No. GLOW is a single co-formulated blend (one vial, 70 mg total, 5:1:1) supplied in vial and nasal-spray formats, dosed as one product.
How much of each compound does a dose deliver?
Injection (10 units once daily): GHK-Cu 1.67 mg, BPC-157 0.33 mg, TB-500 0.33 mg. Spray (3 sprays once daily): GHK-Cu 1.5 mg, BPC-157 0.3 mg, TB-500 0.3 mg. See the breakdown section.
How is GLOW reconstituted?
Injection: 70 mg in 3 mL BAC water → 23.3 mg/mL, dose 10 units (0.10 mL). Spray: 70 mg in 10 mL → 0.7 mg blend per spray, ~3 sprays per dose.
Why is the TB-500 amount lower than its standalone dose?
GLOW is GHK-Cu-led at 5:1:1, so the TB-500 share lands at a lighter maintenance level. Researchers wanting a fuller TB-500 dose sometimes add standalone TB-500.
What is the pen-vial format?
A 70 mg GLOW pen vial supplied already reconstituted to 3 mL. That is the same fill the injection protocol above assumes, so a 10-unit dose still delivers GHK-Cu 1.67 mg, BPC-157 0.33 mg and TB-500 0.33 mg. Per unit the pen carries 33 / 167 / 33 mcg of BPC-157 / GHK-Cu / TB-500.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
GLOW Formats & Sourcing
The protocols above are written against the formats GLOW is actually supplied in. Batch-specific Certificates of Analysis are issued per lot; always verify the strength on the label against the figures used here before calculating anything.
| Format | Supplied as |
|---|---|
| Vial | 70 mg lyophilized blend |
| Pen vial | Pre-reconstituted, 3 mL |
| Nasal spray | Pre-mixed, 0.7 mg blend per spray |
| Nasal spray — 5-pack | Bulk: five nasal spray units |
| Vial — 5-pack | Bulk: five vial units |
5-packs are available for the nasal spray and vial formats. Strengths and formats are listed as sold; confirm against the product page and the batch COA.
Reference material for this protocol, with batch COA:
View GLOW on Spyro Peptides →References
- Pickart L, Margolina A. Regenerative actions of the GHK-Cu peptide. Int J Mol Sci (2018).
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des (2011).
- Goldstein AL, et al. Thymosin β4 and tissue repair. Ann N Y Acad Sci (2012).
- Component-level dosing references compiled on the linked GHK-Cu, BPC-157, and TB-500 pages.